ACA
HRTX icon

Avoro Capital Advisors’s Heron Therapeutics HRTX Stock Holding History

Avoro Capital Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-150,000
Closed -$5M – 38
2015
Q2 		$4.67M Buy
+150,000
New +$2.82M 1.29% 21
2015
Q1 		– Sell
-65,900
Closed -$663K – 38
2014
Q4 		$663K Buy
+65,900
New +$538K 0.45% 26

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avoro Capital Advisors's HRTX Position: Q3 2015 in Review

Avoro Capital Advisors sold out of Heron Therapeutics (HRTX) in Q3 2015, closing a stake of 150,000 shares — an estimated $5M sold.

Avoro Capital Advisors first reported a position in HRTX in Q4 2014 and held it in 2 quarters. The position peaked at $4.67M in Q2 2015. 102 funds tracked by Wall St. Rank hold HRTX as of Q3 2015.

  • Avoro Capital Advisors reported no remaining Heron Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Avoro Capital Advisors sold 150,000 Heron Therapeutics shares in Q3 2015, an estimated $5M.
  • Avoro Capital Advisors first reported a position in Heron Therapeutics in Q4 2014 and held it in 2 quarters.
  • Avoro Capital Advisors's Heron Therapeutics position peaked at $4.67M in Q2 2015.
  • 102 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2015.

Based on Avoro Capital Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.